Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Neoadjuvant Therapy for Limited-Stage Small Cell Esophageal Carcinoma
NCT07155122Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of serplulimab in small cell carcinoma of the esophagus (SCEC), sponsored by Fujian Medical University Cancer Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
small cell carcinoma of the esophagus (SCEC)
Beyond the preview
Go deeper on NCT07155122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07155122.